Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics, with the goal of disrupting existing treatment paradigms to improve patient outcomes
Family
Family 1 / MSP-1014: Psilocybin-like conjugate.
Family 2: High-potency, short-acting, psilocybin-like.
Family 3: Low-potency, long-duration for micro-dosing
Family 4: DMT/ 5-MeO-DMT-inspired compounds
Lead Identification
Lead Optimization
IND-Enabling
Clinical Phase 1
Click to enlarge
Family/Product
Lead Identification
Lead Optimization
IND-Enabling
Clinical Phase 1
Clinical Indication /
Phase 1 Timing
Psilocybin-like conjugate.
Family#1
MSP-1014
TR Depression &
Terminal Cancer Angst
High-potency, short-acting, psilocybin-like.
Family#2
Partnered
DMT/ 5-MeO-DMT-inspired compounds
Family#4
Low-potency, long-duration for micro-dosing
Family#3
Indications related to
cognitive / attentional
impairments; TBD
